(2023)
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
TRANSLATIONAL LUNG CANCER RESEARCH.
12,
12
(2023)
Systematic analysis of Mendelian disease-associated gene variants reveals new classes of cancer-predisposing genes
(교신저자이나 논문 출판사에서 교신저자 표시 누락으로 출판 수정 요청중입니다. 추후 인센티브 신청하겠습니다.).
GENOME MEDICINE.
15,
1
(2023)
Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer.
SCIENTIFIC REPORTS.
13,
1
(2023)
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
ESMO OPEN.
8,
6
(2023)
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.
CANCERS.
15,
22
(2023)
Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients.
SCIENTIFIC REPORTS.
13,
1
(2023)
Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
JOURNAL OF TRANSLATIONAL MEDICINE.
21,
1
(2023)
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
CANCERS.
15,
20
(2023)
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY.
18,
9
(2023)
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8<SUP>+</SUP> T Cells.
ADVANCED SCIENCE.
10,
17
(2023)
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
NEW ENGLAND JOURNAL OF MEDICINE.
389,
6
(2023)
Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
MODERN PATHOLOGY.
36,
7
(2023)
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY.
-,
-
(2023)
Lung adenocarcinoma promotion by air pollutants.
NATURE.
616,
7955
(2023)
Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers.
CANCER MEDICINE.
12,
7
(2023)
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
11,
2
(2023)
MHC II immunogenicity shapes the neoepitope landscape in human tumors.
NATURE GENETICS.
55,
2
(2023)
Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
FRONTIERS IN IMMUNOLOGY.
13,
(2022)
Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
CANCER MEDICINE.
12,
6
